A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

NCT05318326 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: placebo group
DRUG: Yogliptin 400mg group
DRUG: Yogliptin 200mg group

Sponsor

Chengdu Easton Biopharmaceuticals Co,Ltd